Orchard Therapeutics Ltd.

https://www.orchard-tx.com

Orchard Therapeutics, a Kyowa Kirin company, is focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Its team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. *

	Start	2015-09-02 established
	Group	Kyowa Kirin (Group)
	Industry	gene therapy
	Industry 2	DRUGS, ORPHAN
	Person	Rothera, Mark (Freeline Therapeutics –202202 CEO before Orchard Therapeutics + PTC Tx + Aegerion + Shire RESIGNED 2/22)
	Person 2	Thomas, Frank (Orchard Therapeutics 201801– CFO + CBO before AMAG Pharmaceuticals + Molecular Biometrics Inc)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	108 Cannon Street
	City	EC4N 6EU London
	Tel	+44-203-384-6700
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Annogen B.V.. (6/4/24). "Press Release: Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters". Amsterdam.

		Record changed: 2024-06-07